T1	p 19 43	hyaline membrane disease
T2	p 244 268	hyaline membrane disease
T3	p 394 428	gestation . Twelve control animals
T4	p 455 479	of dexamethasone-treated
T5	p 548 566	infants of control
T6	p 667 681	males than for
T7	p 690 691	.
T8	p 788 826	the infants from dexamethasone-treated
T9	p 1024 1061	in infants from dexamethasone-treated
T10	p 1621 1622	.
T11	i 81 106	antenatal dexamethasone .
T12	i 147 161	glucocorticoid
T13	i 215 234	Macaca nemestrina )
T14	i 275 278	) .
T15	i 286 290	dams
T16	i 300 325	dexamethasone ( 2 mg/dose
T17	i 438 446	saline .
T18	i 827 831	dams
T19	i 852 860	dry lung
T20	i 1141 1149	dry lung
T21	i 1250 1258	dry lung
T22	i 1341 1360	phosphatidylcholine
T23	i 1363 1368	DPC )
T24	i 1390 1398	dry lung
T25	i 1512 1525	dexamethasone
T26	i 1621 1646	. Antenatal dexamethasone
T27	i 1727 1730	HMD
T28	o 480 484	dams
T29	o 509 531	incidence and severity
T30	o 707 731	volume-pressure behavior
T31	o 762 784	greater distensibility
T32	o 906 934	enhanced deflation stability
T33	o 952 977	Accelerated production of
T34	o 1004 1023	SAM ) phospholipids
T35	o 1062 1066	dams
T36	o 1097 1120	total lung phospholipid
T37	o 1203 1228	lavage fluid phospholipid
T38	o 1329 1360	disaturated phosphatidylcholine
T39	o 1363 1366	DPC
T40	o 1443 1456	Incorporation
T41	o 1556 1563	portion
T42	o 1688 1710	incidence and severity
T43	o 1823 1864	maturation of fetal pulmonary functions ,
T44	o 1922 1940	SAM phospholipid .